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Abstract
Background:  Chronic kidney disease (CKD) is becoming a major public health problem
worldwide. This article reviews the published evidence of prevalence of CKD in population-based
study samples that used the standardized definition from the Kidney Disease Outcomes Quality
Initiative of the National Kidney Foundation (K/DOQI) practice guideline, and particularly focus on
performance of serum-creatinine based equations for GFR estimation. We provide a summary of
available data about the burden of CKD in various populations.
Methods:  We performed a systematic review of available published data in MEDLINE. A
combination of various keywords relevant to CKD was used in this research. Related data of
included studies were extracted in a systematic way.
Results: A total of 26 studies were included in this review. The studies were conducted in different
populations, and the number of study participants ranged from 237 to 65181. The median
prevalence of CKD was 7.2% in persons aged 30 years or older. In persons aged 64 years or older
prevalence of CKD varied from 23.4% to 35.8%. Importantly, the prevalence of CKD strongly
depended on which estimating equations were used. The Modification of Diet in Renal Disease
Study (MDRD) equation was likely to be preferred in recent epidemiological studies compared to
the adjusted Cockcroft-Gault (CG) equation.
Conclusion:  Worldwide, CKD is becoming a common disease in the general population.
Accurately detecting CKD in special groups remains inadequate, particularly among elderly
persons, females or other ethnic groups such as Asians.
Background
Chronic kidney disease (CKD) is becoming a major public
health problem worldwide. The current burden of disease
might due to a change of the underlying pathogenicity of
CKD. Glomerulonephritis was the one of the leading
causes of kidney disease several decades ago. Nowadays,
infections have become a less important cause for kidney
disease, at least in the western world [1]. Moreover, cur-
rent evidence suggests that hypertension and diabetes are
the two major causes of kidney disease worldwide [2,3].
Given the pathogenic progression of kidney disease,
patients with CKD are at high risk for progression to the
end stage renal disease (ESRD) – a condition requiring
dialysis or kidney transplantation to maintain patients'
long-term survival. In 2001, the average annual cost for
maintenance of ESRD therapy was between US $70 and
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$75 billion worldwide excluding kidney transplantation,
and the predicted number of ESRD patients will reach
over 2 million in 2010 [4]. The enormous costs of treat-
ment lead to a large burden for the health care systems,
particularly in developing countries.
In addition, CKD has a complicated interrelationship
with other diseases [5]. Recent studies have reported that
CKD is an independent risk factor for cardiovascular dis-
ease (CVD) [6]. Therefore, kidney dysfunction should be
an additional target for intervention and prevention of
CVD [7]. In 2003, the American Heart Association (AHA)
stated that persons with CKD should be regarded as the
highest risk group for subsequent CVD [8].
Due to the asymptomatic nature of this disease, CKD is
not frequently detected until its later progress, resulting in
lost opportunities for prevention. Progress to kidney fail-
ure or other adverse outcomes could be prevented or
delayed through early detection and treatment of CKD
[9,10].
Currently, large efforts have been made to a better detec-
tion of progressive kidney disease. In 2002 the Kidney
Disease Outcomes Quality Initiative (K/DOQI) of the
National Kidney Foundation (NKF) developed a practice
guideline for CKD [11]. According to this guideline, CKD
is defined as either kidney damage or glomerular filtration
rate (GFR) below 60 ml/min/1.73 m2 for three or more
months with or without evidence of kidney damage, irre-
spective of the cause [12]. GFR is estimated by serum cre-
atinine based on equations rather than on direct
measurements. Several equations have been developed
and the most frequently used ones are the Cockcroft-
Gault (CG) equation and the Modification of Diet in
Renal Disease Study (MDRD) equation. Both equations
are currently considered to be the best methods to esti-
mate GFR for adults in epidemiologic studies [13-15].
A number of epidemiologic studies assessed the preva-
lence of CKD in different populations and used different
equations to estimate kidney function. This article reviews
the recently published data on the prevalence of CKD in
population-based study samples that used the standard-
ized definition from K/DOQI practice guideline, particu-
larly focuses on performance of estimating equations for
GFR such as the MDRD equation and the CG equation,
and provides a summary for the burden of CKD.
Methods
Search strategy
A systematic literature search was conducted in the
MEDLINE database (US National Library of Medicine,
Bethesda, Maryland) to identify all potentially relevant
publications before July 2006. The following words were
used for this search: "chronic kidney (or renal) disease",
"kidney (or renal) disease", "kidney (or renal) dysfunc-
tion", "decreased kidney (renal) function", "glomerular
filtration rate", "Cockcroft-Gault equation", "MDRD
equation", "prevalence", and "population" or "commu-
nity". Reference lists of primary original studies and
review articles were also checked whether any further
related articles could be found (cross-references).
Study selection
Inclusion criteria were designed to find studies that
reported the prevalence of CKD in the general population.
Studies were included when carried out in a representative
sample of the general population, and when the defini-
tion of CKD was based on the K/DOQI practice guideline.
We excluded studies with a sample size of less than 50 par-
ticipants, studies without GFR estimation by serum creat-
inine-based equations, and studies that provided only
serum creatinine concentration. Information published
only in abstract form was not included, as the abstracts
usually do not provide all necessary information to evalu-
ate the quality of a study.
Definition of chronic kidney disease
We used the definition of CKD from the K/DOQI practice
guideline that was published in 2002 by the National Kid-
ney Foundation (NKF). CKD was defined as CrCl or GFR
less than 60 ml/min/1.73 m2 [11,12].
Although CrCl is different from GFR, it is commonly used
as an estimation value in practice after adjusting for body
surface area (BSA); therefore, we also used CrCl to assess
the outcome, and compared CrCl with GFR.
The two equations were defined in the following way:
Simplified MDRD equation [15,16]: GFR (ml/min/1.73
m2) = 186.3 * (serum creatinine)-1.154  * (age)-0.203  *
(0.742 if female) * (1.21 if African American).
CG/BSA equation [14]: Creatinine Clearance (ml/min) =
(140 – age)/(serum creatinine) * (weight/72) * (0.85 if
female), which is further standardized for body surface
area (BSA) according to the Dubois and Dubois formula
[17]: BSA (m2) = 0.20247 * height (m) 0.725 * weight (kg)
0.425. Creatinine Clearance is also expressed as ml/min/
1.73 m2.
Serum creatinine is measured in mg/dl, age in years,
weight in kg, and GFR is expressed as ml/min/1.73 m2.
Data extraction
Two investigators reviewed each paper independently.
Discrepancies were discussed and agreement was achieved
by consensus. When possible, the prevalence of CKD wasBMC Public Health 2008, 8:117 http://www.biomedcentral.com/1471-2458/8/117
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extracted as an overall value and stratified by estimating
equations, by age categories and by gender. In some
included studies, the prevalence of CKD was not directly
stated but available from published figures or calculated
from other available information of the articles. We pre-
sented the prevalence of CKD based on GFR estimation
only, although both GFR estimation and proteinuria were
reported in some of the included studies.
Results
Study characteristics
We retrieved 71 publications of potential interest for this
review, of which 45 studies were excluded (Fig 1). Finally,
we identified 26 articles fulfilling our inclusion criteria
[18-43]. Ten studies were from America (Table 1) [18-27],
8 studies were from Europe (Table 2) [28-35], and 8 were
from Asia and Australia (Table 3) [36-43]. The number of
participants in the included studies ranged from 237 to
65181 [41,30]. The subjects of included studies were all
adults (≥ 18 years old); 4 studies assessed the prevalence
of CKD among elderly persons over 63 years old
[23,24,26,35], and 10 studies among middle and old-
aged persons (≥ 30 years old) [25,27,28,34,37-40,42,43].
Two studies were based on the data from the NHANES III
study, but used different time periods (1988–1994 and
1999–2000); both of these were included in this review
[20,21].
We extracted the prevalence of CKD from 19 cross-sec-
tional studies [18-21,23,25,29-32,34-41,43], and 7 stud-
ies that were based on a cohort study design [22,24,26-
28,33,42]. The assessment of the prevalence of CKD was
not the major study object in some of the included stud-
ies. Some mainly determined the association between
CKD and other risk factors, such as cardiovascular diseases
[18,22,25,26,31,32,41], diabetes [18], and life style fac-
Flow diagram of studies Figure 1
Flow diagram of studies.
Articles retrieved for more 
detailed evaluation (n=49) 
Reason for exclusion:  
 No standard definition of CKD 
(n=23) 
Studies included (N=26) 
Reason for exclusion:  
No original data (n=5) 
Not a population based study (n=8) 
Data presented in other article (n=9) 
Potentially relevant publications 
identified and screened (n=71) B
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Table 1: Prevalence of chronic kidney disease (CKD) in population-based studies from America
Prevalence of CKD
Author [ref.] year Country Study population, study design, number of participants, 
response, age, gender
MDRD equation CG/BSA equation
Amato et al. [18] 2005 Mexico Randomly selected participants from primary care facilities in a 
large city, cross-sectional study, N = 3564, response NR, aged 
>18 yrs., gender NR.
NR Overall: 8.5%
Brown et al. [19] 2005 USA Participants of the Kidney Early Evaluation Program (KEEP) in 
33 states, cross-sectional study, N = 6071, response NR, aged 
18–101 yrs. (mean age: 52 yrs.), 32% males.
Overall: 15.6%
Men: 14.4%, Women: 16.2%
NR
Age (yrs.) Men Women
18–30 2.4% 2.7%
31–45 5.4% 6.4%
46–60 9.5% 11.5%
61–75 24.3% 29.9%
76+ 45.6% 45.0%
Coresh et al. [20] 2005 USA Participants of the Third National Health and Nutrition 
Examination Survey (NHANES III, 1999–2000), cross-sectional 
study, N = 4101, response NR, aged ≥ 20 yrs., 47.7% males.
Overall: 3.8%
Men: 2.7%, women: 4.8%
White: 4.2%, African American: 3.4%, Mexican 
American: 1.2%, other: 3.2%
NR
Age (yrs.)
20–39 0.5%
40–59 1.5%
60–69 6.2%
70+ 23.1%
Coresh et al. [21] 2003 USA Participants of the Third National Health and Nutrition 
Examination Survey (NHANES III 1988–1994), cross-sectional 
study, N = 15600, response NR, aged ≥ 20 yrs., 47% males.
Overall: 4.5%
Men: 3.6%, Women: 5.3%
White: 5.0%, African American: 3.3%, Mexican 
American: 1.0%, other: 2.2%
Overall: 7.0%
Men: 6.3%, Women: 7.7%
White: 7.5%, African American: 7.8%, Mexican 
American: 1.8%, other: 4.1%
Age (yrs.) Age (yrs.)
20–39 0.2% 20–39 -
40–59 1.8% 40–59 0.8%
60–69 7.6% 60–69 10.5%
70+ 24.9% 70+ 49.2%
Fox et al. [22] 2006 USA Participants from the sixth examination of the Framingham 
Offspring Study, cohort study, N = 3047, response NR, mean 
age: 59 yrs., 48% males.
Overall: 8.6% NRB
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Garg et al. [23] 2004 Canada Participants from long-term care facilities in the elderly, 
retrospective cross-sectional study, N = 9931, response 85%, 
aged ≥ 65 yrs. (mean age: 82 yrs.), 26% males.
Overall: 35.7%
Men: 27.1%, Women: 38.8%
NR
Age (yrs.) Men Women
65–69 9.2% 22.8%
70–74 14.9% 23.8%
75–79 21.7% 29.2%
80–84 27.5% 35.2%
85–89 32.8% 41.9%
90–94 40.5% 47.3%
95+ 37.8% 50.7%
Hemmelgarn et al. [24] 
2006
Canada Participants from community-dwelling elderly in Calgary 
Health region, cohort study, N = 10184, response NR, aged ≥ 
66 yrs., 42.6% males.
Overall: 35.4%
Men: 32%, Women: 38.2%
NR
Kramer et al. [25] 2005 USA Participants of the Dallas Heart Study, cross-sectional survey, 
N = 2660, response NR, aged 30–65 yrs.(mean age: 43.9 yrs.), 
49.5% males.
Overall: 1.5% NR
Manjunath et al. [26] 
2003
USA Participants of the Cardiovascular Health Study 
(CHS), cohort study, N = 4893, response NR, aged ≥ 
65 yrs. (mean age: 75.4 yrs.), 44.5% males.
Overall: 23.4%
Men: 25%, Women: 22.2%
NR
McClellan et al. [27] 
2006
USA Randomly selected participants of the Reasons for 
Geographic and Racial Differences in Stroke 
(REGARDS) study, cohort study, N = 20667, 
response NR, aged ≥ 45 yrs., 48.8% males.
Overall: 43.3%
Men: 38.9%, Women: 47.5% White: 49.9%, 
African American: 33.7%
NR
Age (yrs.)
45–54 19.3%
55–64 31.6%
65–74 51.3%
75–84 62.7%
85+ 71.0%
MDRD: simplified equation of the Modification of Diet in Renal Disease Study.
CG/BSA: Cockcroft-Gault formula adjusted by Body Surface Area.
GFR: Glomerular Filtration Rate. NR: Not reported.
Table 1: Prevalence of chronic kidney disease (CKD) in population-based studies from America (Continued)B
M
C
 
P
u
b
l
i
c
 
H
e
a
l
t
h
 
2
0
0
8
,
 
8
:
1
1
7
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
5
8
/
8
/
1
1
7
P
a
g
e
 
6
 
o
f
 
1
3
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 2: Prevalence of chronic kidney disease (CKD) in population-based studies from Europe
Prevalence of CKD
Author [ref.] year Country Study population, study design, number of participants, response, age, gender MDRD equation CG/BSA equation
Brugts et al. [28] 2005 Netherlands Participants of the Rotterdam Study, prospective cohort study, N = 4484, 
response 78%, aged ≥ 55 yrs. (mean age: 69.6 yrs.), 36.3% males.
NR Overall: 44.9%
Cirillo et al. [29] 2006 Italy Participants from central Italy, cross-sectional study, N = 4574, response NR, 
aged 18–95 yrs., 45.5% males.
Overall: 6.4%
Men: 6.5%, Women: 6.2%
NR
Age (yrs.) Men Women
18–44 0.6% 1.3%
45–54 2.6% 1.3%
55–64 7.3% 5.4%
65–74 15.0% 11.0%
75+ 34.5% 31.6%
Hallan et al. [30] 2006 Norway Participants of the second Health Survey of Nord-Trondelag County (HUNT 
II), cross-sectional study, N = 65181, response 70.4%, aged ≥ 20 yrs. (mean age: 
50.2 yrs.), 46.8% men.
Overall: 4.7%
Men: 3.6%, Women: 5.7%
NR
Age (yrs.)
20–39 0.2%
30–59 1.4%
60–69 6.3%
70+ 18.6%
Nitsch et al. [31] 2006 Switzerland Participants of the Swiss SAPALDIA Study, random sample, cross-sectional 
study, N = 6317, response NR, aged ≥ 18 yrs., 49% males.
Overall: 8.1%
Men: 4.5%, Women: 11.5%
NR
Age (yrs.) Men Women
< 55 1.1% 7.9%
55–65 7.1% 23.5%
66+ 12.9% 35.9%
Otero et al. [32] 2005 Spain Randomly selected participants of the Estudio Epidemioloógic o de la 
Insuficiencia Renal en Espana (EPIRCE) pilot study, cross-sectional study, N = 
237, response NR, aged ≥ 20 yrs. (mean age: 49.58 yrs.), 42.6% males.
Overall: 5.1% NR
Verhave et al. [33] 2004 Netherlands Participants of the Prevention of Renal and Vascular End-stage Disease Study, 
cohort study, N = 6022, response NR, aged 28–75 yrs. (mean age: 48 yrs.), 
51.5% males.
NR Overall: 4.2%
Viktorsdottir et al. [34] 2005 Iceland Participants of the Reykijavik Heart Study, cross-sectional study. N = 19256, 
response NR, aged 33–85 yrs., 48% males.
Overall: 7.2%
Men: 3.7%, Women: 10.9%
Overall: 24.7%
Men: 19%, Women: 30%
Age (yrs.) Men Women
35–39 0.8% 2.2%
40–44 1.1% 3.0%
45–49 1.3% 4.4%
50–54 2.3% 6.3%
55–59 2.4% 7.6%
60–64 5.2% 11.7%
65–69 13.5% 36.1%
70–74 17.0% 38.1%
75–79 19.5% 35.3%
80+ 24.5% 53.1%
Wasen et al. [35] 2004 Finland Participants from elderly residents in a community, cross-sectional study, N = 
1246, response 83%, age 64–100 yrs. (mean age: 74 yrs.), 42% males.
Overall: 35.8% Overall: 58.5%
MDRD: simplified equation of the Modification of Diet in Renal Disease Study.
CG/BSA: Cockcroft-Gault formula adjusted by Body Surface Area.
GFR: Glomerular Filtration Rate.
NR: Not reported.B
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) Table 3: Prevalence of chronic kidney disease (CKD) in population-based studies from Asia and Australia
Prevalence of CKD
Author [ref.] year Country Study population, study design, number of participants, response, age, gender MDRD equation CG/BSA equation
Chadban et al. [36] 2003 Australia Randomly selected participants of the Australian Diabetes, Obesity and Lifestyle Study 
(AusDiab), cross-sectional survey, N = 11247, response 89.1%, aged 25 ≥ yrs., gender 
NR.
NR Overall: 11.2%
Men: 9.3%, Women: 
13.0%
Age (yrs.) Men Women
25–44 - 0
45–64 1.8% 3.2%
65+ 51.8% 57.2%
Chen et al. [37] 2005 China Participants of the International Collaborative Study of Cardiovascular Disease in Asia 
(InterASIA), random sample, cross-sectional study, N = 15540, response 83.3%, aged 
35–74 yrs., 48.5% males.
Overall: 2.5%
Men: 1.3%, Women: 3.8%
Overall: 20.4%
Age (yrs.) Men Women
35–44 0.2% 1.2%
45–54 0.7% 2.7%
55–64 1.6% 6.4%
65–74 5.8% 10.4%
Domrongkitchaiporn et al. 
[38] 2005
Thailand Participants of the Electricity Generating Authority of Thailand (EGAT) study, 
employees sample, cross-sectional study, N = 2967, response NR, aged 35–55 yrs., 76% 
males.
Overall: 6.8% NR
Konta et al. [39] 2006 Japan Participants of the Molecular Epidemiological Study, cross-sectional survey, N = 2321, 
response NR, aged > 40 yrs. (mean age: 64 yrs.), 44:5% males.
NR Overall: 28.8%
Li et al. [40] 2006 China Participants from residents in a district of a large city, cross-sectional survey, N = 2310, 
response NR, aged ≥ 40 yrs., 49.5% males.
Overall: 4.9%
Men: 4.8%, Women: 5.0%
NR
Age (yrs.) Men Women
40–49 0 0.4%
50–59 1.5% 2.5%
60–69 4.4% 5.8%
70+ 10.6% 12.9%
McDonald et al. [41] 2003 Australia Participants from a costal aboriginal community, cross-sectional study, N = 237, 
response NR, aged ≥ 18 yrs., 133 males.
Overall: 12% NR
Ninomiya et al. [42] 2005 Japan Participants from study of Cerebrovascular and Cardiovascular Diseases, prospective 
cohort study, N = 2634, response 80.7%, aged ≥ 40 yrs., 42.1% males.
Overall: 10.3%
Men: 5.3%, Women: 13.8%
NR
Shankar et al. [43] 2006 Singa pore Participants from private census, cross-sectional study, N = 4898, response 81.1%, aged 
43–86 yrs. (mean age: 62.3 yrs.), 44% males.
Overall: 6.6%
Men: 7.1%, Women: 6.2%
NR
Age (yrs.)
43–59 1.8%
60–69 6.5%
70–79 11.5%
80+ 21.8%
MDRD: simplified equation of the Modification of Diet in Renal Disease Study.
CG/BSA: Cockcroft-Gault formula adjusted by Body Surface Area.
GFR: Glomerular Filtration Rate.
NR: Not reported.BMC Public Health 2008, 8:117 http://www.biomedcentral.com/1471-2458/8/117
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tors [43], or assessed the difference between estimating
equations for kidney function [35].
Prevalence of CKD
Equation-specific prevalence of CKD
Overall, 17 studies used the MDRD equation [19,20,22-
27,29-32,38,40-43], 5 studies used the CG/BSA equation
[18,28,33,36,39] and 4 studies used both of them
[21,34,35,37]. Eight of 9 studies were published in 2006
with GFR estimation by the MDRD equation. The studies
estimated GFR with both of the MDRD and the CG/BSA
equations among the same population, and all reported a
higher prevalence of CKD with the CG/BSA equation than
with the MDRD equation [21,34,35,37]. A study based on
the NHANES III survey provided the age-specified preva-
lence with both equations [21]. The increase of the preva-
lence with age was notably greater in using the CG/BSA
rather than the MDRD equation, particularly in persons
aged 70 years or older. The differences in the prevalence of
CKD equations seemed much stronger among elderly per-
sons than among younger ones.
Age-specific prevalence of CKD
The prevalence of CKD varied strongly with age. Four
studies were conducted among elderly persons (≥ 64
years) and showed a markedly high prevalence
[23,24,26,35]. Manjunath et al. [26] measured serum
samples from a community-based cohort study and found
a prevalence of 23.4% by use of the MDRD equation for
persons aged 65 years or older. In Canada, a cross-sec-
tional study [23] showed a higher prevalence (35.7%)
than the study of Manjunath et al. [26] in the USA. Mean-
while, Wasén et al. [35] used both MDRD and GC/BSA
equations to estimate GFR in elderly persons in Finland
and reported a much higher prevalence in using the CG/
BSA equation (58.5%) than using the MDRD equation
(35.8%). Another recent study from Canada reported an
overall prevalence of 35.4% in elderly persons aged 66
years or older [24]. Figure 2 shows the prevalence of stages
of CKD in studies conducted in population-based sam-
ples in the elderly with CKD.
Several studies were conducted in middle and old-aged
persons (≥ 30 years old) [27,28,34,37-40,42,43]. The
prevalences of CKD varied from 1.5% to 43.3% in differ-
ent populations (median: 7.2%). The Dallas Heart Study
[25], which included 2660 participants aged from 30 to
65 years old, reported the lowest prevalence of CKD by
means of the MDRD equation (1.5%). The highest preva-
lence was reported from a cohort study among persons
aged 45 years or older in USA (43.3%) [27].
In general, the prevalence of CKD increased with age
within the same study population [19-21,23,27,29-
31,34,37,40,43]. For example, the prevalence of CKD
from the NHANES III study from 1988 to 1994 [21], a
cross-sectional representative survey in USA, was 0.2% in
the age group 20–39 years, 1.8% in the age group 40–59
years, 7.6% in the age group 60–69 years, and 24.9% in
persons aged 70 and older as determined by means of the
MDRD equation. Similar age-related increases of preva-
lence were observed in other studies as well, regardless
which equation was used [19,20,23,27,29-31,37,40,43].
Coresh et al. [20] compared prevalence of CKD from two
surveys of the National Health and Nutrition Examina-
tion Survey (NHANES III) conducted from 1998 to 1994
and 1999 to 2000 separately. They found that the overall
prevalence of CKD was similar in both surveys (4.5%
from 1998 to 1994, 3.8% from 1999 to 2000) and the
proportions of CKD were also comparable with respect to
gender and ethnicity.
Gender-specific prevalence of CKD
Most of the included studies also presented a gender-spe-
cific prevalence of CKD [19, 21, 23, 24, 27, 30, 31, 34, 36,
40, 42, 43]. In general, the prevalence of CKD was greater
in women than in men, regardless of age. A cross-sectional
study reported a higher prevalence of CKD in Swiss
women compared with men (4.5% in men and 11.5% in
women) [31]. Brown et al. [19] reported remarkably high
prevalences in both men and women, but women had a
tendency to have a higher prevalence of CKD than men
(14.4% in men and 16.2% in women, p = 0.09). Chadban
et al. [36] reported a statistically significant gender-differ-
ence of prevalences derived from the AusDiab Study
(9.3% in men and 13.0% in women, p = 0.002). In gen-
eral, a higher prevalence of CKD in women compared
with men was observed across age categories and also in
various ethnic groups.
Ethnic-specific prevalence of CKD
In 3 studies from the USA, the prevalences of CKD were
higher in Caucasians than in African Americans
[20,21,27]. Notably, two studies from NHANES III
reported CKD prevalences with respect to various ethnic
subgroups: Mexican Americans were less likely to have
CKD than African Americans and Caucasians [20,21]. The
ethnic-specific prevalence was 49.9% in 11620 Cauca-
sians and 33.7% in 8139 African Americans from the
REGARDS cohort study [27].
Additionally, 6 studies from four countries in Asia (Thai-
land, China, Singapore and Japan) were conducted in
comparable age groups [37-40,42,43]. Considering the
estimating equations of GFR, a very high prevalence of
CKD was found in a Chinese population (20.4%) [37]
and a Japanese population (28.8%) [39] using the CG/
BSA equation. When the MDRD equation was used, aBMC Public Health 2008, 8:117 http://www.biomedcentral.com/1471-2458/8/117
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lower prevalence was found (mean prevalence: 6.2%) as
seen in other studies [37,38,40,42,43].
Discussion
This systematic review summarized the prevalence of CKD
in various population-based studies, which used a stand-
ardized definition of CKD and considered age-, gender-
and ethnic-specific prevalence of CKD. Overall, the preva-
lence of CKD varied widely among the study populations
and increased clearly with age. In general, females had a
higher prevalence than males, especially in the middle
aged groups. African Americans had a lower prevalence
than Caucasians, and Asian populations had a relatively
high prevalence. More importantly, the prevalence of
CKD strongly depended on the estimating equations; the
prevalence was much higher with the use of the CG/BSA
equation than with the MDRD equation.
Although the burden of CKD seemed quite large in some
studies, less than 2% of the CKD patients progresses to
ESRD according to data from the US [44,45]. However,
patients with early stages of CKD are clearly at risk for car-
diovascular diseases [46]. Several interventions have been
suggested to delay the progression of CKD or to prevent
other complications of CKD, such as low-protein diets,
strict control of blood pressure and proteinuria, smoking
cessation, and the usage of lipid-lowering and anti-
inflammatory medication [9].
Prevalence of CKD and estimating equations
Serum creatinine concentration is the most commonly
used biomarker to predict the level of kidney function, but
it can be affected by various factors such as age, gender,
ethnicity, muscle mass, dietary habit and specific drug
use. The serum creatinine-based equations for GFR esti-
mation overcome some of the limitations of using serum
creatinine alone because they are adjusted for age, gender,
ethnicity, or body size. So far, more than 25 serum creati-
nine-based equations for GFR estimation have been
developed [47]. The MDRD equation and the CG/BSA
equation are the most widely used equations for GFR esti-
mation in practice; thus, we focus discussion on the per-
formance of these two equations.
Lin et al. found that the MDRD equation was more precise
and accurate to estimate GFR in healthy persons com-
pared with the CG equation, but the MDRD equation con-
sistently underestimated GFR and the CG equation
overestimated GFR [48]. The latest study from Levey et al.
calculated differences between estimated and measured
GFR by stages of CKD [49], and reported that the MDRD
equation was substantially better to estimate GFR in per-
sons with CKD and with a measured GFR of less than 90
Prevalence of CKD stages in elderly persons (≥ 64 years) with CKD using the MDRD equation (GFR, ml/min/1.73 m2) Figure 2
Prevalence of CKD stages in elderly persons (≥ 64 years) with CKD using the MDRD equation (GFR, ml/min/1.73 m2). The 
numbers over each bar represent whole prevalence of CKD (GFR < 60 ml/min/1.73 m2).
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ml/min/1.73 m2 compared to the CG/BSA equation. They
also suggested that the use of a standard serum creatinine
assay might improve the accuracy of GFR estimates. In
contrast, a cross-sectional study of Veroort et al. reported
a significant difference between measured GFR and esti-
mated GFR after correcting by means of renal tubular
secreted creatinine in healthy persons (9.0 ml/min/1.73
m2 for CG/BSA equation, 10.7 ml/min/1.73 m2 for the
MDRD equation, p = 0.03) [50]. They concluded that the
MDRD equation was less accurate in estimating GFR than
the CG/BSA equation in persons with a normal GFR.
However, the result should be carefully considered
because of the small sample size of the study (n = 46).
Meanwhile, Rule et al. showed a weak correlation between
measured GFR and estimated GFR (r = 0.26, p < 0.001 for
the MDRD equation; r = 0.35, p < 0.001 for the CG/BSA
equation) in 365 healthy potential kidney donors [51],
and they concluded that both equations were more or less
inaccurate in healthy persons. Laboratory interferences
and different study settings might partly explain the con-
flicting results.
A review article summarized the available data in 2005
and concluded that the MDRD equation provides a more
accurate and clinical acceptable estimation of GFR than
the CG equation in patients with GFR less than 60 ml/
min/1.73 m2  [47]. However, the CG/BSA equation is
superior to the MDRD equation in terms of long time-
period use in practice. Since the CG equation was pub-
lished in 1976, it has been the most widely used equation
in clinical practice, especially in drug dosage adjustments
[14]. Later, it was adjusted to the body surface area (BSA)
according to the Dubois and Dubois formula [17]. The
adjustment for BSA had no affect on the accuracy of per-
formance of the CG equation [48]. The MDRD equation
was published in 1999 [15] and is widely used in clinical
practice and epidemiologic studies [52]. Considering that
these two equations were derived from patients with CKD,
further studies should investigate for an improved predic-
tion equation for GFR estimation in persons with normal
or mildly decreased kidney function [53].
Prevalence of CKD and personal characteristics
Age presents one of the most important factors that affect
kidney function. Generally, kidney function is stable after
infancy until late adulthood [54]. GFR declines by 1 ml/
min/1.73 m2 per year after the age of 30 years in healthy
persons [5]. The decrease in kidney function might be due
to the changes in the kidney structure associated with
aging [55]. In the included studies, the elderly had a mark-
edly higher prevalence of CKD and the prevalence
increased with age in all populations, particularly among
elderly persons aged 70 years or older. This steep increase
in the prevalence of CKD in the elderly might be partly
due to related comorbidities of CKD, such as cardiovascu-
lar diseases or diabetes. Moreover, the serum creatinine
concentration remains within the normal range until a
significant decrease of kidney function, especially in the
elderly [56]. Serum creatinine is not a sensitive marker of
GFR in older persons. In addition to the substantial effect
of age on the kidney structure and kidney function, the
same GFR level might have different pathophysiologic or
non-pathophysiologic effects on kidney function in differ-
ent age groups.
Furthermore, a gender-different prevalence of CKD was
revealed in most included studies. Females had a higher
prevalence of CKD than males. Females have less muscle
mass as compared to males and the muscle mass is a
major determinant of serum creatinine concentration
[57]. Some risk factors for CKD in favour of males are
unlikely to explain the difference between females and
males, e.g. the prevalences of smoking and alcohol con-
sumption, as well as the prevalence of cardiovascular dis-
eases, which are generally higher in males than in females.
The higher prevalence of CKD might partly be the result of
an inaccurate correction factor for females in both equa-
tions. Additionally, the difference between females and
males in glomerular structure, glomerular haemodynam-
ics, and the hormone metabolism might play an impor-
tant role in the gender disparity [58]. However, some
uncertainties about the validity of prediction equations
still remain, particularly when they are used in females.
CKD in different ethnic groups
Both equations were developed from defined study popu-
lations. In the CG equation, no information on ethnicity
was considered [14]. The MDRD equation was developed
from study participants with only 12% of participants
being African Americans [15,16]. In the US, the age-
adjusted rate of ESRD for African Americans was almost 4
times higher than that for American Caucasians [59]. Li et
al. concluded that the ethnical difference in the incidence
of ESRD might partly be due to a higher prevalence of pri-
mary causal diseases of ESRD (e.g. diabetes, hyperten-
sion) and lower access to health care measures in African
Americans as compared to American Caucasians [60].
McClellan et al. [27] investigated the ethnic difference of
CKD in a population-based cohort of subjects aged 45
years or older and found that African Americans had a
lower prevalence of CKD in early stages of CKD, but had
a high prevalence of ESRD. They speculated that this dis-
parity might be caused by different access to health care,
poor control of other related risk factors, or differences in
genetic factors, environmental exposures or life style.
Studies hypothesized that the lower CKD prevalence in
African Americans as compared to Caucasians might be
due to impaired renal development and fewer nephrons
resulting from a larger incidence of low birth weight in
African Americans [61-63] or due to hyperfiltration andBMC Public Health 2008, 8:117 http://www.biomedcentral.com/1471-2458/8/117
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faster progression of CKD in African Americans [20,44]; it
might also be the result of genetic differences, lifestyle dif-
ference, or different comorbidity, but the exact mecha-
nisms remain unclear. Although the ethnical disparity
could due to the different performance of GFR estimation
equations in various ethnic groups, a recent study
reported that the MDRD equation showed only little bias
in African Americans [64].
We found unexpectedly higher prevalences of CKD when
using the CG/BSA equation in Chinese and Japanese pop-
ulations than in the US population. Interestingly, Chen et
al. reported a large difference in the prevalence of CKD
using the MDRD and the CG/BSA equations (2.5% using
MDRD, 20.4% using CG/BSA) in the same study popula-
tion from China [37]. Similar equation-differences were
seen in 2 Japanese studies (10.3% using MDRD, 28.8%
using CG/BSA) [39,42]. Zou et al. evaluated the validity of
the MDRD and the CG/BSA equations among the Chinese
population, and they suggested that further studies
should be performed to determine the exact correction
factor for CKD among the Chinese [65]. The original
MDRD equation has been modified in China and Japan
by specific coefficients [66-68]. A recent study in China
developed a cystatin C-based equation for GFR estimation
and combined serum creatinine and cystatin C measure-
ment to improve accuracy of GFR estimation [69].
One of the included studies in the review assessed kidney
function with cystatin C in elderly persons [35]. Cystatin
C is under investigation as a promising marker for serum
creatinine in estimating GFR [70,71]. More recent
research has focused on the development of cystatin C-
based equations for GFR estimation in the elderly and in
different clinical setting such as in patients with diabetes
and patients with cardiovascular disease et al. [72,73].
When looking on the results of our review the following
limitations should be considered. Our primary interest
was to identify all studies conducted in a population-
based setting using a standard definition of CKD from the
K/DOQI guideline to give an overview over the current sit-
uation of CKD worldwide. However, the differences in the
prevalence of comorbidities and/or other factors related
to risk of CKD, such as the prevalence of cardiovascular
diseases, diabetes, infection, or lifestyle and socioeco-
nomic factors, might affect the prevalence of CKD [74].
We were not able to take the underlying prevalence of
these factors into account in the present review; further
studies should be conducted and investigate them in
more detail. It should be noted that the prevalence of
CKD might be underestimated in the present review
because other indications of kidney damage such as pro-
teinuria were not considered by most of the included
studies. In addition, the response quote should also be
considered, which was only available in some of the stud-
ies. Reliable creatinine measurement in GFR is critical to
the diagnosis of CKD. Different assays of creatinine meas-
urement make it difficult to compare the prevalence of
CKD across studies directly and having a worldwide
standardization would provide a major improvement for
the comparison of epidemiological studies.
Conclusion
In conclusion, despite the disparities of GFR estimation,
CKD is already a common disease in the worldwide gen-
eral population. However, accurate detection of CKD in
special subgroups remains inadequate. Besides putting
more efforts to estimate GFR accurately in the general
population, further studies should validate the means of
GFR estimation in elderly persons, in females and in dif-
ferent ethnical groups. Additionally, the use of new
emerging biomarkers like cystatin C should be an impor-
tant issue in further studies of CKD.
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